Document is current
Any future updates will be listed below
-
Authors
Izgutdina, Adila https://orcid.org/0000-0002-3296-3261
Rashid, Tasfia
Temple, William C https://orcid.org/0000-0003-3375-2703
Aminov, Sarah
Patiño-Escobar, Bonell
Walunj, Sujata
Geng, Huimin
Takamatsu, Hiroyuki
Gil-Alós, Daniel
Kang, Amrik S
Ramos, Emilio
Chen, Szu-Ying
Johnson, Haley
Nix, Matthew A
Naik, Akul
Li, Mingcheng
Yuan, Constance M
Wang, Hao-Wei
Sahu, Srabani
Larson, Rebecca C https://orcid.org/0000-0003-0174-061X
Carpenter, Christopher
Salangsang, Fernando
Phojanakong, Paul
Serrano, Juan Antonio Camara
Tariq, Isa
Zakraoui, Ons
Steri, Veronica
Valeri, Antonio
Martinez-Lopez, Joaquin
Maus, Marcela V https://orcid.org/0000-0002-7578-0393
Parekh, Samir
Verma, Amit
Shah, Nirali N https://orcid.org/0000-0002-8474-9080
Wiita, Arun P https://orcid.org/0000-0002-7465-6964
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03448393 at ClinicalTrials.govnct03827343 at ClinicalTrials.govDocuments that mention this clinical trial
Impact of fludarabine exposure on the depth and duration of lymphopenia and CAR T-cell outcomes.
https://doi.org/10.1200/jco.2023.41.16_suppl.10033
Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignancies
https://doi.org/10.1136/jitc-2025-012013
CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results
https://doi.org/10.1136/jitc-2026-015296
<i>CRLF2</i> -rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy
https://doi.org/10.1136/jitc-2024-009499
Documents that mention this clinical trial
Pre-infusion risk factors predict severe infectious complications of CAR T-cell therapy in pediatric and adult patients with B-ALL
https://doi.org/10.1136/jitc-2025-012436
Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation
https://doi.org/10.1136/jitc-2021-004483
Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignancies
https://doi.org/10.1136/jitc-2025-012013
-
Funding
Funding for this research was provided by:
Intramural Research Program, Center of Cancer Research, National Cancer Institute and NIH Clinical Center (N/A)
Harold Amos Physician-Scientist Development Program Award (N/A)
Alex’s Lemonade Stand Center of Excellence (N/A)
California Institute of Regenerative Medicine, UCSF Alpha Clinic Physician Scientist Research Fellowship Award (N/A)
UCSF Medical Scientist Training Program (T32GM141323)
Contrato Río Hortega by the Instituto de Salud Carlos III (CM24/00094)
TERAV+ by RICORS/TERAV (RD24/0014/0003)
Baszucki Lymphoma Therapeutics Initiative (N/A)
Dept. of Defense Congressionally Directed Medical Research Program Award (W81XWH2210807)
American Society of Hematology Research Training Award for Fellows (N/A)
UCSF Helen Diller Family Comprehensive Cancer Center Preclinical Therapeutic Core Facility (P30CA082103)
Chan Zuckerberg Biohub Physician-Scientist Fellowship Program (N/A)
National Institute of Health (ZIA BC 011823)
UCSF Living Therapeutics Initiative (N/A)
American Society of Transplantation and Cellular Therapy New Investigator Award (N/A)
Multiple Myeloma Research Foundation Translational Accelerator Award (N/A)
NIH (T32AI007529)
- License Information
